B. Landesmann

发表

Putative adverse outcome pathways relevant to neurotoxicity

K. Crofton, A. Rolaki, C. Suñol, 2015, Critical reviews in toxicology.

Representing the Process of Inflammation as Key Events in Adverse Outcome Pathways.

R. Pieters, T. Lawrence, P. Allavena, 2018, Toxicological sciences : an official journal of the Society of Toxicology.

Towards a 21st-century roadmap for biomedical research and drug discovery: consensus report and recommendations.

Martin Hofmann-Apitius, Brigitte Landesmann, Christoph Giese, 2017, Drug discovery today.

SEURAT-1 liver gold reference compounds: a mechanism-based review

Michael Schwarz, Brigitte Landesmann, Paul Jennings, 2014, Archives of Toxicology.

Systematic Organization of COVID-19 Data Supported by the Adverse Outcome Pathway Framework

Stephen W. Edwards, C. Willett, Clemens Wittwehr, 2021, Frontiers in Public Health.

Systematic Organization of COVID-19 Data Supported by the Adverse Outcome Pathway Framework

Stephen W. Edwards, C. Willett, Clemens Wittwehr, 2021, Frontiers in Public Health.

Understanding COVID-19 through adverse outcome pathways - 2nd CIAO AOP Design Workshop.

Laure-Alix Clerbaux, N. Garcia-Reyero, Clemens Wittwehr, 2021, ALTEX.

Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework

D. Greco, Laure-Alix Clerbaux, M. C. Albertini, 2022, Journal of clinical medicine.

Mechanistic Understanding of the Olfactory Neuroepithelium Involvement Leading to Short-Term Anosmia in COVID-19 Using the Adverse Outcome Pathway Framework

Laure-Alix Clerbaux, K. Kanninen, S. Coecke, 2022, Cells.

Adverse Outcome Pathway on Protein Alkylation Leading to Liver Fibrosis

B. Landesmann, 2016 .

Title Protein Alkylation leading to Liver Fibrosis Short name : Protein Alkylation to Liver Fibrosis

B. Landesmann, 2015 .

Building and Applying Quantitative Adverse Outcome Pathway Models for Chemical Hazard and Risk Assessment

Edward J Perkins, Roman Ashauer, Lyle Burgoon, 2019, Environmental toxicology and chemistry.

JRC Summer School on Non-animal Approaches in Science, May 2021

B. Landesmann, A. Paini, 2021, Alternatives to laboratory animals : ATLA.

Adverse Outcome Pathway-based Screening Strategies for an Animal-free Safety Assessment of Chemicals

Brigitte Landesmann, Elisabet Berggren, Maurice Whelan, 2013, Alternatives to laboratory animals : ATLA.

Sex Differences in Liver Toxicity—Do Female and Male Human Primary Hepatocytes React Differently to Toxicants In Vitro?

M. Whelan, T. Palosaari, B. Landesmann, 2015, PloS one.

SEURAT-1 liver gold reference compounds: a mechanism-based review

P. Jennings, M. Schwarz, M. Leonard, 2014, Archives of Toxicology.

Adverse outcome pathway (AOP) development I: strategies and principles.

Sharon Munn, Brigitte Landesmann, Daniel L Villeneuve, 2014, Toxicological sciences : an official journal of the Society of Toxicology.

Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury.

Imran Shah, Brigitte Landesmann, Vera Rogiers, 2013, Toxicological sciences : an official journal of the Society of Toxicology.

How Adverse Outcome Pathways Can Aid the Development and Use of Computational Prediction Models for Regulatory Toxicology

Maurice Whelan, Hugh J. Byrne, Alicia Paini, 2016, Toxicological sciences : an official journal of the Society of Toxicology.

Adverse outcome pathway development from protein alkylation to liver fibrosis

Sharon Munn, Brigitte Landesmann, Tomislav Horvat, 2016, Archives of Toxicology.

The Adverse Outcome Pathway approach in nanotoxicology

Sharon Munn, Brigitte Landesmann, Maurice Whelan, 2017 .

Adverse outcome pathway development II: best practices.

Sharon Munn, Brigitte Landesmann, Daniel L Villeneuve, 2014, Toxicological sciences : an official journal of the Society of Toxicology.

Building shared experience to advance practical application of pathway-based toxicology: liver toxicity mode-of-action.

Thomas Hartung, Imran Shah, Jennifer Seed, 2014, ALTEX.

Pathway-based toxicity: history, current approaches and liver fibrosis and steatosis as prototypes.

Brigitte Landesmann, Catherine Willett, Jessica Caverly Rae, 2014, ALTEX.

Building and Applying Quantitative Adverse Outcome Pathway Models for Chemical Hazard and Risk Assessment

Cheryl A. Murphy, Roman Ashauer, E. Perkins, 2019, Environmental toxicology and chemistry.

COVID-19 through Adverse Outcome Pathways: Building Networks to Better Understand the Disease – 3rd CIAO AOP Design Workshop

Young Jun Kim, Holly M. Mortensen, M. Vinken, 2022, ALTEX.

Building shared experience to advance practical application of pathway-based toxicology: liver toxicity mode-of-action.

Katy O Goyak, M. Vinken, P. Watkins, 2014, ALTEX.

How Adverse Outcome Pathways Can Aid the Development and How Adverse Outcome Pathways Can Aid the Development and Use of Computational Prediction Models for Regulatory Use of Computational Prediction Models for Regulatory Toxicology Toxicology

E. Heinzle, G. Ankley, B. Landesmann, 2022 .